- Home
- TOI vs APRE Comparison
TOI vs APRE Comparison
Compare TOI & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOI
- APRE
- Stock Information
- Founded
- TOI 2007
- APRE 2006
- Country
- TOI United States
- APRE United States
- Employees
- TOI N/A
- APRE N/A
- Industry
- TOI Medical/Nursing Services
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TOI Health Care
- APRE Health Care
- Exchange
- TOI Nasdaq
- APRE Nasdaq
- Market Cap
- TOI 22.7M
- APRE 20.2M
- IPO Year
- TOI N/A
- APRE 2019
- Fundamental
- Price
- TOI $0.32
- APRE $2.65
- Analyst Decision
- TOI Strong Buy
- APRE Strong Buy
- Analyst Count
- TOI 1
- APRE 2
- Target Price
- TOI $2.50
- APRE $15.50
- AVG Volume (30 Days)
- TOI 73.8K
- APRE 13.6K
- Earning Date
- TOI 11-06-2024
- APRE 11-07-2024
- Dividend Yield
- TOI N/A
- APRE N/A
- EPS Growth
- TOI N/A
- APRE N/A
- EPS
- TOI N/A
- APRE N/A
- Revenue
- TOI $361,067,000.00
- APRE $1,275,686.00
- Revenue This Year
- TOI $29.17
- APRE $96.15
- Revenue Next Year
- TOI $16.43
- APRE N/A
- P/E Ratio
- TOI N/A
- APRE N/A
- Revenue Growth
- TOI 23.31
- APRE 410.91
- 52 Week Low
- TOI $0.27
- APRE $2.25
- 52 Week High
- TOI $2.66
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- TOI 47.54
- APRE 35.09
- Support Level
- TOI $0.29
- APRE $2.55
- Resistance Level
- TOI $0.34
- APRE $3.19
- Average True Range (ATR)
- TOI 0.02
- APRE 0.22
- MACD
- TOI 0.01
- APRE -0.02
- Stochastic Oscillator
- TOI 65.42
- APRE 42.24
About TOI The Oncology Institute Inc.
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).